Study of Adjuvant ONO-4538 With Resected Gastric Cancer
NCT ID: NCT03006705
Last Updated: 2024-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
800 participants
INTERVENTIONAL
2017-01-31
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ONO-4538 in Gastric Cancer
NCT02746796
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
NCT02267343
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
NCT02872116
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05144854
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nivolumab group
Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.
S-1 therapy(maximum 1 year):
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
CapeOX Therapy(maximum 6 months):
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Nivolumab
Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Tegafur-gimeracil-oteracil potassium
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Oxaliplatin
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Placebo group
Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.
S-1 therapy(maximum 1 year):
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
CapeOX Therapy(maximum 6 months):
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Tegafur-gimeracil-oteracil potassium
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Oxaliplatin
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Placebo
Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Tegafur-gimeracil-oteracil potassium
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Oxaliplatin
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Placebo
Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients without a remnant cancer (R0) who have undergone gastrectomy
* Gastric carcinoma according to the stage classification of AJCC/UICC TNM Classification, 7th Edition on the basis of overall postoperative findings
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
Exclusion Criteria
* Multiple primary cancers
* A current or past history of severe hypersensitivity to any other antibody products
* Any concurrent autoimmune disease or past history of chronic or recurrent autoimmune disease
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Project Leader
Role: STUDY_DIRECTOR
Ono Pharmaceutical Co. Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anhui Province Clinical Site
Anhui Province, , China
Beijing Clinical Site1
Beijing, , China
Beijing Clinical Site2
Beijing, , China
Cuangdong Province Clinical Site
Cuangdong Province, , China
Guangdong Province Clinical Site1
Guangdong Province, , China
Guangdong Province Clinical Site2
Guangdong Province, , China
Henan Province Clinical Site1
Henan Province, , China
Henan Province Clinical Site2
Henan Province, , China
Jiangsu Province Clinical Site1
Jiangsu Province, , China
Jiangsu Province Clinical Site3
Jiangsu Province, , China
Jiangsu Province Clinical Site4
Jiangsu Province, , China
Jiangsu Province Clinical Site5
Jiangsu Province, , China
Jiangsu Province Clinical Site6
Jiangsu Province, , China
Jiangxi Province Clinical Site2
Jiangxi Province, , China
Jilin Province Clinical Site
Jilin Province, , China
Liaoning Province Clinical Site
Liaoning Province, , China
Shanxi Province Clinical Site
Shanxi Province, , China
Tianjin Clinical Site1
Tianjin, , China
Tianjin Clinical Site2
Tianjin, , China
Zhejiang Province Clinical Site
Zhejiang Province, , China
Zhengjiang Province Clinical Site
Zhengjiang Province, , China
Aichi Clinical Site1
Nagoya, Aichi-ken, Japan
Aichi Clinical Site2
Nagoya, Aichi-ken, Japan
Chiba Clinical Site
Kamogawa, Chiba, Japan
Ehime Clinical Site
Matsuyama, Ehime, Japan
Ehime Clinicla Site
Matsuyama, Ehime, Japan
Gifu Clinical Site
Ōgaki, Gifu, Japan
Gunma Clinical Site
Ōta, Gunma, Japan
Gunma Clinical Site
Takasaki, Gunma, Japan
Hiroshima Clinical Site
Fukuyama, Hiroshima, Japan
Hokkaido Clinical Site 3
Hakodate, Hokkaido, Japan
Hokkaido Clinical Site 1
Sapporo, Hokkaido, Japan
Hokkaido Clinical Site2
Sapporo, Hokkaido, Japan
Hyogo Clinical Site
Akashi, Hyōgo, Japan
Hyogo Clinical Site
Amagasaki, Hyōgo, Japan
Hyogo Clinical Site
Nishinomiya, Hyōgo, Japan
Ishikawa Clinical Site
Kanazawa, Ishikawa-ken, Japan
Iwate Clinical Site
Morioka, Iwate, Japan
Kanagawa Clinical Site
Sagamihara, Kanagawa, Japan
Kanagawa Clinical Site
Yokohama, Kanagawa, Japan
Miyagi Clinical Site
Ōsaki, Miyagi, Japan
Nagano Clinical Site
Saku, Nagano, Japan
Okayama Clinical Site
Kurashiki, Okayama-ken, Japan
Osaka Clinical Site
Hirakata, Osaka, Japan
Osaka Clinical Site
Ōsaka-sayama, Osaka, Japan
Osaka Clinical Site
Sakai, Osaka, Japan
Osaka Clinical Site
Suita, Osaka, Japan
Osaka Clinical Site
Takatsuki, Osaka, Japan
Osaka Clinical Site
Toyonaka, Osaka, Japan
Saitama Clinical Site
Hidaka, Saitama, Japan
Saitama Clinical Site
Kitaadachi-gun, Saitama, Japan
Shizuoka Clinical Site
Sunto-gun, Shizuoka, Japan
Tochigi Clinical Site
Shimotsuke, Tochigi, Japan
Tokyo Clinical Site
Bunkyo-ku, Tokyo, Japan
Tokyo Clinical Site
Chuo-ku, Tokyo, Japan
Tokyo Clinical Site
Koto-ku, Tokyo, Japan
Tokyo Clinical Site
Shinjuku-ku, Tokyo, Japan
Chiba Clinical Site
Chiba, , Japan
Fukuoka Clinical Site 1
Fukuoka, , Japan
Fukuoka Clinical Site 2
Fukuoka, , Japan
Gifu Clinical Site
Gifu, , Japan
Hiroshima Clinical Site1
Hiroshima, , Japan
Hiroshima Clinical Site2
Hiroshima, , Japan
Hiroshima Clinical Site3
Hiroshima, , Japan
Kochi Clinical Site
Kochi, , Japan
Kumamoto Clinical Site
Kumamoto, , Japan
Kyoto Clinical Site
Kyoto, , Japan
Niigata Clinical Site
Niigata, , Japan
Osaka Clinical Site1
Osaka, , Japan
Osaka Clinical Site2
Osaka, , Japan
Osaka Clinical Site3
Osaka, , Japan
Osaka Clinical Site4
Osaka, , Japan
Shizuoka Clinical Site
Shizuoka, , Japan
Toyama Clinical Site
Toyama, , Japan
Wakayama Clinical Site
Wakayama, , Japan
Yamagata Clinical Site
Yamagata, , Japan
Busan Clinical Site1
Busan, , South Korea
Busan Clinical Site2
Busan, , South Korea
Busan Clinical Site3
Busan, , South Korea
Daegu Clinical Site1
Daegu, , South Korea
Daegu Clinical Site2
Daegu, , South Korea
Daegu Clinical Site3
Daegu, , South Korea
Daejeon Clinical Site 1
Daejeon, , South Korea
Daejeon Clinical Site 2
Daejeon, , South Korea
Gwangju Clinical Site
Gwangju, , South Korea
Gyeonggi-do Clinical Site1
Gyeonggi-do, , South Korea
Gyeonggi-do Clinical Site2
Gyeonggi-do, , South Korea
Gyeonggi-do Clinical Site3
Gyeonggi-do, , South Korea
Gyeonggi-do Clinical Site4
Gyeonggi-do, , South Korea
Gyeonggi-do Clinical Site5
Gyeonggi-do, , South Korea
Jeollabuk-do Clinical Site
Jeollabuk-do, , South Korea
Seoul Clinical Site 8
Seoul, , South Korea
Seoul Clinical Site 9
Seoul, , South Korea
Seoul Clinical Site1
Seoul, , South Korea
Seoul Clinical Site2
Seoul, , South Korea
Seoul Clinical Site3
Seoul, , South Korea
Seoul Clinical Site4
Seoul, , South Korea
Seoul Clinical Site5
Seoul, , South Korea
Seoul Clinical Site6
Seoul, , South Korea
Seoul Clinical Site7
Seoul, , South Korea
Kaohsiung Clinical Site2
Kaohsiung City, , Taiwan
Kaohsiung Clinical Site
Kaohsiung City, , Taiwan
New Taipei Clinical Site
New Taipei City, , Taiwan
Taichung Clinical Site
Taichung, , Taiwan
Tainan Clinical Site2
Tainan City, , Taiwan
Tainan Clinical Site
Tainan City, , Taiwan
Taipei Clinical Site1
Taipei, , Taiwan
Taipei Clinical Site2
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18.
Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-4538-38
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.